Loading...
XSHG
600276
Market cap53bUSD
Aug 12, Last price  
60.85CNY
1D
-0.36%
1Q
15.03%
Jan 2017
108.63%
IPO
171.29%
Name

Jiangsu Hengrui Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
60.88
P/S
13.78
EPS
1.00
Div Yield, %
0.33%
Shrs. gr., 5y
—
Rev. gr., 5y
3.74%
Revenues
27.98b
+22.63%
1,179,259,5571,422,456,9041,959,660,1212,392,561,1593,028,960,8813,744,106,2694,550,391,7685,435,067,5616,203,074,3557,452,253,0879,315,960,16811,093,724,12113,835,629,36917,417,901,05023,288,576,60727,734,598,74725,905,526,37521,275,270,68122,819,784,74127,984,605,342
Net income
6.34b
+47.28%
162,222,057206,647,797412,921,287422,947,064665,730,889724,173,302876,611,0611,077,384,7641,238,110,6351,515,568,8632,171,571,5452,588,952,0953,216,647,9984,065,609,7165,328,027,5196,328,383,2194,530,217,5503,906,375,0674,302,435,9306,336,527,014
CFO
7.42b
-2.89%
227,876,230266,175,427218,873,724117,459,736439,116,229385,945,810527,357,720958,368,8911,364,958,6661,574,306,0242,277,293,1222,592,628,3952,547,385,4162,774,212,7343,816,832,8673,431,934,8054,218,816,0531,265,264,6317,643,665,0747,422,753,038
Dividend
Jul 12, 20240.2 CNY/sh
Earnings
Aug 20, 2025

Profile

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
URL
https://www.hengrui.com/
IPO date
Oct 18, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
27,984,605
22.63%
22,819,785
7.26%
21,275,271
-17.87%
Cost of revenue
15,986,124
18,342,513
17,471,868
Unusual Expense (Income)
NOPBT
11,998,482
4,477,271
3,803,403
NOPBT Margin
42.88%
19.62%
17.88%
Operating Taxes
832,695
389,289
153,421
Tax Rate
6.94%
8.69%
4.03%
NOPAT
11,165,786
4,087,982
3,649,982
Net income
6,336,527
47.28%
4,302,436
10.14%
3,906,375
-13.77%
Dividends
(1,019,873)
(1,014,797)
Dividend yield
0.36%
0.41%
Proceeds from repurchase of equity
(827,265)
(398,028)
BB yield
0.29%
0.16%
Debt
Debt current
1,260,943
Long-term debt
138,072
150,353
197,721
Deferred revenue
225,650
38,950
119,440
Other long-term liabilities
2
Net debt
(26,409,598)
(22,047,134)
(16,412,510)
Cash flow
Cash from operating activities
7,422,753
7,643,665
1,265,265
CAPEX
(1,483,792)
Cash from investing activities
1,222,315
390,289
Cash from financing activities
(3,144,426)
FCF
11,955,642
6,711,230
1,591,918
Balance
Cash
25,089,250
20,845,155
17,871,175
Long term investments
1,458,420
1,352,332
Excess cash
25,148,440
21,056,498
16,807,411
Stockholders' equity
40,814,920
35,768,386
35,424,979
Invested Capital
21,236,497
20,090,715
22,965,808
ROIC
54.04%
18.99%
17.31%
ROCE
25.80%
10.86%
9.54%
EV
Common stock shares outstanding
6,336,527
6,327,112
6,367,002
Price
45.90
1.48%
45.23
17.39%
38.53
-24.02%
Market cap
290,846,590
1.63%
286,175,260
16.65%
245,320,590
-24.18%
EV
265,007,381
264,695,417
229,497,428
EBITDA
12,774,512
5,181,907
4,381,296
EV/EBITDA
20.75
51.08
52.38
Interest
5,559
6,655
6,492
Interest/NOPBT
0.05%
0.15%
0.17%